Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biopharmaceutical company based in Sarasota, Florida, dedicated to the discovery and development of a novel class of anti-infective agents. The company's proprietary technology platform, known as Bisphosphocins™, consists of synthetic, small-molecule compounds designed to address the growing global threat of multi-drug resistant (MDR) bacterial, viral, and fungal infections. Unlike traditional antibiotics that often target specific metabolic pathways, Bisphosphocins utilize a unique mechanism of action that rapidly disrupts the bacterial cell membrane. This physical mode of action makes it significantly more difficult for pathogens to develop resistance, offering a potential breakthrough for patients who have exhausted conventional treatment options. The company's lead product candidate, Nu-3, is being developed as a topical and systemic antimicrobial. It has been studied for the treatment of infected diabetic foot ulcers and other chronic wounds where biofilm and resistant bacteria are prevalent. Beyond wound care, Lakewood-Amedex is exploring the application of its platform for respiratory tract infections and other systemic indications. The company aims to leverage its intellectual property and clinical data to form strategic partnerships and advance its pipeline through the regulatory approval process to meet the urgent need for effective new anti-infectives.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!